Abemaciclib
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma
Conditions
Glioblastoma
Trial Timeline
Feb 9, 2017 → Jun 30, 2026
NCT ID
NCT02981940About Abemaciclib
Abemaciclib is a phase 2 stage product being developed by Eli Lilly for Glioblastoma. The current trial status is active. This product is registered under clinical trial identifier NCT02981940. Target conditions include Glioblastoma.
What happened to similar drugs?
1 of 18 similar drugs in Glioblastoma were approved
Approved (1) Terminated (1) Active (16)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02792725 | Pre-clinical | Completed |
| NCT03763604 | Pre-clinical | Completed |
| NCT06025747 | Phase 1 | Recruiting |
| NCT06678269 | Phase 1 | Recruiting |
| NCT04003896 | Phase 2 | Terminated |
| NCT04408924 | Phase 2 | Completed |
| NCT04681768 | Pre-clinical | Completed |
| NCT03891784 | Phase 2 | Active |
| NCT03837821 | Phase 1 | Active |
| NCT03339843 | Phase 2 | Completed |
| NCT03703466 | Phase 2 | Completed |
| NCT03310879 | Phase 2 | Recruiting |
| NCT02919696 | Phase 1 | Completed |
| NCT03130439 | Phase 2 | Terminated |
| NCT02981940 | Phase 2 | Active |
| NCT02846987 | Phase 2 | Active |
| NCT02482935 | Phase 1 | Completed |
| NCT02308020 | Phase 2 | Completed |
| NCT02387814 | Phase 1 | Completed |
| NCT02102490 | Phase 2 | Completed |
Competing Products
20 competing products in Glioblastoma